IRIS
SALADINI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.237
EU - Europa 5.902
AS - Asia 2.734
SA - Sud America 542
Continente sconosciuto - Info sul continente non disponibili 265
AF - Africa 170
OC - Oceania 5
Totale 16.855
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.072
RU - Federazione Russa 1.296
GB - Regno Unito 1.205
IT - Italia 1.113
SG - Singapore 844
CN - Cina 767
IE - Irlanda 692
BR - Brasile 441
SE - Svezia 417
VN - Vietnam 331
DE - Germania 287
FR - Francia 262
HK - Hong Kong 256
UA - Ucraina 219
IN - India 123
FI - Finlandia 120
KR - Corea 99
ES - Italia 96
ZA - Sudafrica 95
CA - Canada 83
BD - Bangladesh 63
NL - Olanda 42
BE - Belgio 37
AR - Argentina 35
MX - Messico 35
TR - Turchia 34
JP - Giappone 33
PL - Polonia 28
IQ - Iraq 24
NG - Nigeria 24
LT - Lituania 21
PK - Pakistan 20
UZ - Uzbekistan 18
ID - Indonesia 16
EC - Ecuador 15
CO - Colombia 14
VE - Venezuela 14
AT - Austria 12
CZ - Repubblica Ceca 12
IR - Iran 12
JM - Giamaica 11
KE - Kenya 11
AE - Emirati Arabi Uniti 10
KZ - Kazakistan 10
EG - Egitto 9
GR - Grecia 9
PH - Filippine 9
HN - Honduras 8
MA - Marocco 8
PY - Paraguay 8
SA - Arabia Saudita 8
EE - Estonia 7
BO - Bolivia 6
CR - Costa Rica 6
ET - Etiopia 6
SK - Slovacchia (Repubblica Slovacca) 6
IL - Israele 5
MY - Malesia 5
NP - Nepal 5
PT - Portogallo 5
AL - Albania 4
BH - Bahrain 4
CL - Cile 4
DO - Repubblica Dominicana 4
JO - Giordania 4
LV - Lettonia 4
OM - Oman 4
PA - Panama 4
TH - Thailandia 4
TN - Tunisia 4
AU - Australia 3
DZ - Algeria 3
GT - Guatemala 3
LB - Libano 3
PE - Perù 3
PR - Porto Rico 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
AO - Angola 2
AZ - Azerbaigian 2
BW - Botswana 2
CI - Costa d'Avorio 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
SN - Senegal 2
SV - El Salvador 2
TM - Turkmenistan 2
AM - Armenia 1
AW - Aruba 1
BY - Bielorussia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EU - Europa 1
GE - Georgia 1
GP - Guadalupe 1
GY - Guiana 1
Totale 16.578
Salva come PNG Salva come JPEG
Città #
Southend 1.017
Dallas 864
Dublin 687
Fairfield 627
Ashburn 572
Singapore 461
San Jose 411
Chandler 391
Moscow 357
Santa Clara 347
Woodbridge 270
Hong Kong 246
Beijing 245
Siena 236
Seattle 230
Cambridge 224
Milan 219
Ann Arbor 214
Houston 211
Wilmington 201
Jacksonville 182
Council Bluffs 143
New York 129
Los Angeles 119
Munich 117
Rome 112
Princeton 111
Ho Chi Minh City 102
Hefei 99
Seoul 96
Johannesburg 89
Hanoi 69
Lauterbourg 69
Málaga 66
The Dalles 63
Helsinki 59
Boardman 51
Nanjing 48
São Paulo 46
Columbus 44
San Mateo 44
Buffalo 38
Shanghai 37
Bengaluru 36
Dong Ket 33
London 32
Brussels 31
Montreal 31
Orem 31
San Diego 31
Dearborn 27
Tokyo 27
Hangzhou 25
North Bergen 25
Abuja 23
Portsmouth 22
Atlanta 21
Chennai 21
Denver 21
Frankfurt am Main 21
Redondo Beach 21
Warsaw 21
Turku 20
Menlo Park 19
Nanchang 19
Phoenix 19
Toronto 19
Manchester 17
Mexico City 17
Tashkent 17
Chicago 16
Figino 16
Naples 16
Nuremberg 16
Brooklyn 14
Redwood City 14
San Francisco 14
Stockholm 14
Amsterdam 13
Boston 13
Brasília 13
Florence 13
Fremont 13
Mumbai 13
Shenyang 13
Düsseldorf 12
Izmir 12
Belo Horizonte 11
Dhaka 11
Hebei 11
Lancaster 11
Lappeenranta 11
Baghdad 10
Da Nang 10
Norwalk 10
Tianjin 10
Turin 10
Vilnius 10
Changsha 9
Rio de Janeiro 9
Totale 10.978
Salva come PNG Salva come JPEG
Nome #
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 340
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 325
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 320
A novel methodology for large-scale phylogeny partition 317
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 315
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 311
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 310
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 309
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 308
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 299
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 297
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 275
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 271
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 269
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 269
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 269
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 264
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 263
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 262
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 259
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 256
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients 255
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 254
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 252
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 252
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 251
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 250
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 247
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 247
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 238
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 236
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 235
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 233
Identification of novel 2-benzoxazolinone derivatives with specific inhibitory activity against the HIV-1 nucleocapsid protein 233
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 232
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 231
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 230
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors 221
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 219
Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project) 210
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 208
Impact of extensive HIV-1 variability on molecular diagnosis in the Congo Basin 207
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 204
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 203
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients 202
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 200
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry 199
Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study 199
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 195
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 186
PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests” 174
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 170
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 168
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 165
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 165
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects 165
Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 164
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects. 163
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 154
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 153
Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes 152
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 151
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 150
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 147
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 139
Recombination analysis and structure prediction show correlation between breakpoint clusters and RNA hairpins in the pol gene of HIV-1 unique recombinant forms 132
null 129
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 125
null 121
Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen 116
null 114
null 114
Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network) 107
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance 104
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 104
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 96
HIV-1 A1 subtype epidemic in Italy originated from Africa and Eastern Europe and shows a high frequency of transmission chains involving intravenous drug users 86
Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study 86
Marked decrease in acquired resistance to antiretrovirals in latest years in Italy 84
HIV-1 nucleocapsid inhibitors 75
Identification of a possible ancestor of the subtype A1 HIV type 1 variant circulating in the former Soviet Union (Aids Research and Human Retroviruses) 52
Molecular Epidemiology of HIV-1 in Eastern Europe and Russia 46
null 32
All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry 22
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry 21
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 19
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 19
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry 18
Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia 16
Totale 16.855
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.811
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.811
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022857 0 0 0 117 78 50 63 54 71 109 114 201
2022/20231.326 72 186 143 155 129 236 69 95 96 79 43 23
2023/20241.061 33 24 75 65 15 302 376 31 4 18 25 93
2024/20252.279 50 94 294 115 282 171 78 142 206 114 236 497
2025/20265.845 402 746 757 776 1.259 198 554 187 199 292 127 348
2026/20271.102 260 146 370 326 0 0 0 0 0 0 0 0
Totale 16.855